M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
Aegera commences Phase IIb study of AEG35156 for treatment of acute myeloid leukemia
19 November 2009 - Canadian clinical-stage biotechnology company Aegera Therapeutics Inc said today it has started dosing of the first patient in a randomised Phase IIb study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
The study,...
If you want to view the full text of this story, you must first purchase archive retrieval credits.